Multicentric Cohort of Melanoma Patients in Ile de France Area

Study Overview
=================
Brief Summary
-----------------
This is a multicentric prospective cohort of all stage melanoma patients from AP-HP ,the largest consortium of University hospitals over Europe. 7 investigation sites (7 dermatological services of AP-HP) in Ile de France region are involved. 1300 patients will be enrolled and be followed during 10 years.

Detailed Description
-----------------
Melan-Cohort should constitute the first multicentric cohort with various objectives: prognostic, therapeutic, cognitive and medico-economical studies on melanoma. Patients will be recruited in all of the dermatology departments of APHP (dermatology departments from AMBROISE PARE, Saint-Louis, BICHAT-Claude Bernard,Henri-Mondor, Cochin-Tarnier, and Tenon hospitals). For all included patients, a standard file is filled comprising all anatomy-clinical useful data and epidemiologic ones, including sun exposures. Blood is harvested to collect DNA, RNA, serum, plasma at inclusion and at regular intervals and in case of progressive disease. Procedures for sentinel lymph node biopsies have been homogenized. An informed consent is obtained for each patient included in the cohort. A steering committee meets on a regular basis, and genetics or pathology subgroups have been constituted. An electronic CRF is available using the Intranet of APHP hospitals. Specimens are stored using high quality standards.

Official Title
-----------------
Multicentric Cohort of Melanoma Patients in Ile de France Area

Conditions
-----------------
Melanoma, Genetic Polymorphism

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria : age ≥ 18 years an informed consent is obtained patients with anatomy-pathologically proved melanoma the tissue sample of melanoma is available the primary melanoma is treated according to the international standard absence of a progressive non neoplastic pathology involving life-threatening patient living in Ile de France region. time limit to entry in the cohort must be: within 3 months after Surgical resumption of primary melanoma; within 3 months after curative surgical treatment; with one month after diagnosis of a transit metastasis or a distant metastasis. Exclusion criteria : refusal of the patient pathology sample isn't available primary melanoma not being treated according to the international standard patient living too far to follow regular visits patient diagnosed with a progressive non neoplastic pathology involving life-threatening too late to entry and lack of useful stored specimens to research.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival (0-10 years) Disease free survival (0-10 years) |  | 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Invasion of sentinel lymph node biopsy |  | 2003-2009 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
skin cancer, melanoma, sentinel lymph node biopsy, bio bank, genetic polymorphism, prospective cohort, cohort, sentinel lymph nodes, tissue samples